Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4813)	7/7/1998 7:23:00 PM
From: Peter Singleton	Read Replies (1) of 6136

Steve! AG3340 just went into pivotal trials ... 500+ patients, PII/III (lead-in dose ranging PII, then continue onto PIII) ... AGPH cut over immediately from PI. They must have some optimism with regard to the product, and must have some basis for that optimism. It's way too early to expect any inklings about AG3340, except that the company appears to be very positive about the product, and is aggressively pursuing its development. But don't expect any news until sometime next year or the following year. That's just inherent in drug development. There's no other company that would tell you otherwise. gotta be patient on this one ... Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next